Answers are grounded in this paper and cite their sources.
A loss to follow-up of 22% would not bias conclusions about overall treatment effects and, importantly, there were no indications of worse outcomes in non-respondents.
No takes yet. Share an insight, caveat, or question.
Solberg et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: